Bellevue Asset Management’s AYTU BioPharma AYTU Stock Holding History

Bellevue Asset Management’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$68.3K	Hold	25,013	–	–	0.03%	132
2025 Q4	$65K	Buy	+25,013	New	+$56.1K	0.02%	131
2021 Q3	–	Sell	-13	Closed	-$1K	–	582
2021 Q2	$1K	Hold	13	–	–	﹤0.01%	560
2021 Q1	$2K	Hold	13	–	–	﹤0.01%	555
2020 Q4	$2K	Hold	13	–	–	﹤0.01%	573
2020 Q3	$3K	Hold	13	–	–	﹤0.01%	470
2020 Q2	$4K	Buy	+13	New	+$3.94K	﹤0.01%	415

Other funds holding AYTU

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

CAM

Crown Advisors Management Larkspur, California $151M AUM 73.11% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAP

Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Asset Management's AYTU Position: Q1 2026 in Review

Bellevue Asset Management held its AYTU BioPharma (AYTU) position steady in Q1 2026 at 25,013 shares worth $68.3K. The position accounts for 0.03% of the portfolio, ranked #132.

Bellevue Asset Management first reported a position in AYTU in Q2 2020 and has held it in 7 quarters since. 37 funds tracked by Wall St. Rank hold AYTU as of Q1 2026.

Bellevue Asset Management held 25,013 shares of AYTU BioPharma worth $68.3K as of Q1 2026.
Bellevue Asset Management left its AYTU BioPharma share count unchanged in Q1 2026.
AYTU BioPharma made up 0.03% of Bellevue Asset Management's portfolio in Q1 2026, its #132 holding.
Bellevue Asset Management first reported a position in AYTU BioPharma in Q2 2020 and has held it in 7 quarters since.
37 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2026.

Based on Bellevue Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.